Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation

Molecular Cancer

Volumn 4, Issue , 2005, Pages

  Smith, Eric ^a   Drew, Paul A ^b   Tian, Zi Qing ^c   De Young, Neville J ^a   Liu, Jun Feng ^c   Mayne, George C ^b   Ruszkiewicz, Andrew R ^d   Watson, David I ^b   Jamieson, Glyn G ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c HEBEI MEDICAL UNIVERSITY   (China)

^d INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; METALLOTHIONEIN III; GROWTH INHIBITOR; NERVE PROTEIN;

ADULT; AGE; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; DNA METHYLATION; DOWN REGULATION; DRINKING BEHAVIOR; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENDER; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; SURVIVAL TIME; TUMOR VOLUME; CELL LINE; DRUG EFFECT; ESOPHAGUS TUMOR; GENETICS; LYMPHOCYTE; METABOLISM; MIDDLE AGED; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE; DNA METHYLATION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC;

EID: 29244447735     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-4-42     Document Type: Article

References (25)

1. Hamer DH: Metallothionein. Annu Rev Biochem 1986, 55:913-951.
2. Kagi JH, Hunziker P: Mammalian metallothionein. Biol Trace Elem Res 1989, 21:111-118.
3. You HJ, Oh DH, Choi CY, Lee DG, Hahm KS, Moon AR, Jeong HG: Protective effect of metallothionein-III on DNA damage in response to reactive oxygen species. Biochim Biophys Acta 2002, 1573:33-38.
4. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M: The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino, acid metallothionein-like protein. Neuron 1991, 7:337-347.
5. Amoureux MC, Wurch T, Pauwels PJ: Modulation of metallothionein-III mRNA content and growth rate of rat C6-glial cells by transfection with human 5-HT1D receptor genes. Biochem Biophys Res Commun 1995, 214:639-645.
6. Palmiter RD: Constitutive expression of metallothionein-III (MT-III), but not MT-I, inhibits growth when cells become zinc deficient. Toxicol Appl Pharmacol 1995, 135:139-146.
7. Dutta R, Sens DA, Somji S, Sens MA, Garrett SH: Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. Prostate 2002, 52:89-97.
8. Gurel V, Sens DA, Somji S, Garrett SH, Nath J, Sens MA: Stable transfection and overexpression of metallothionein isoform 3 inhibits the growth of MCF-7 and Hs578T cells but not that of T-47D or MDA-MB-231 cells. Breast Cancer Res Treat 2003, 80:181-191.
9. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
10. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999, 21:163-167.
11. Deng D, El-Rifai W, Ji J, Zhu B, Trampont P, Li J, Smith MF, Powel SM: Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 2003, 24:25-29.
12. Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997, 25:2532-2534.
13. Wong DJ, Foster SA, Galloway DA, Reid BJ: Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol 1999, 19:5642-5651.
14. Qian XC, Brent TP: Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 1997, 57:3672-3677.
15. Kinugasa S, Smith E, Drew PA, Watson DI, Jamieson GG: Aspirin and indomethacin for the prevention of experimental port-site metastases. Surg Endosc 2004, 18:834-838.
16. Boyes J, Bird A: Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J 1992, 11:327-333.
17. Kass SU, Goddard JP, Adams RL: Inactive chromatin spreads from a focus of methylation. Mol Cell Biol 1993, 13:7372-7379.
18. Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT, Jones PA: The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998, 58:1245-1252.
19. Hsieh CL: Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol 1994, 14:5487-5494.
20. Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, Todd JH, Sens DA: Metallothionein isoform. 3 as a potential biomarker for human bladder cancer. Environ Health Perspect 2000, 108:413-418.
21. Sens MA, Somji S, Garrett SH, Beall CL, Sens DA: Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 2001, 159:21-26.
22. El-Rifai W, Frierson HF, Jr., Harper JC, Powell SM, Knuutila S: Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer 2001, 92:832-838.
23. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T: Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993, 119:441-449.
24. Smith E, Bianco-Miotto T, Drew P, Watson D: Method for optimizing methylation-specific MR. Biotechniques 2603, 35:32-33.
25. Hussey DJ, Moore S, Nicola M, Dobrovic A: Fusion of the NUP98 gene with the LEDGF/p52 gene defines a recurrent acute myeloid leukemia translocation. BMC Genet 2001, 2:20.